New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

CPLX1 Polyclonal Antibody, PerCP-Cy7 Conjugated

Applications

  • WB
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Mouse
  • Rat

Predicted Reactivity

  • Human
  • Cow
  • Pig
  • Chicken
Overview
Catalog # bs-11341R-PerCP-Cy7
Product Name CPLX1 Polyclonal Antibody, PerCP-Cy7 Conjugated
Applications WB, IF(IHC-P), IF(IHC-F), IF(ICC)
Reactivity Mouse, Rat
Predicted Reactivity Human, Cow, Pig, Chicken
Specifications
Conjugation PerCP-Cy7
Host Rabbit
Source KLH conjugated synthetic peptide derived from human CPLX1
Immunogen Range 31-100/134
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Subcellular location Cytoplasm
Synonyms complexin 1; Complexin I; Complexin-1; CPLX1; CPLX1_HUMAN; CPX I; CPX-I; CPX1; Synaphin 2; Synaphin-2; 921-S.
Background Complexin 1 and Complexin 2, also designated Synaphin 1 and Synaphin 2, contain an a-helical middle domain of approximately 58 amino acids. Complexin 1 and Complexin 2 are expressed in presynaptic terminals of inhibitory and excitatory hippocampal neurons, respectively, and in cytoplasmic pools during early stages of development. Complexins promote SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) precomplex formation by binding to synaxin with its a-helical domain. Complexins are important regulators of transmitter release at a late step in calcium dependent neurotransmitter release or immediately after the calcium-triggering step of fast synchronous transmitter release and preceding vesicle fusion. Neurons lacking complexins show reduced transmitter release efficiency due to decreased calcium sensitivity of the synaptic secretion process. Complexin 2 may play a role in LTP (long term potentiation) following tetanic stimulation. A progressive loss of Complexin 2 occurs in the brains of mice carrying the Huntington disease mutation, an autosomal dominant neurodegenerative disorder. Changes in the neurotransmitter release might contribute to the motor, emotional and cognitive dysfunctions seen in these mice.
Application Dilution
WB 1:300-5000
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200